Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the JAK1 inhibitors baricitinib and abrocitinib significantly reduced mechanical alloknesis in a murine model of atopic dermatitis, whereas the JAK2 inhibitor AZ960 had no effect.

This study found that vitiligo elicited the most compassion and curiosity among general adults viewing AI-generated images of chronic skin diseases, while psoriasis was linked to higher perceptions of disgust and blame.

In this case study, a 5-year-old girl with alopecia areata and atopic dermatitis that were unresponsive to previous treatments achieved substantial improvement with long-term tofacitinib, highlighting its potential safety and efficacy in managing both conditions concurrently.

This study reviewed the literature on atopic dermatitis and found a strong connection with several other skin conditions, such as psoriasis and alopecia areata, while highlighting potential treatments like JAK inhibitors and dupilumab that show promise for these comorbidities.

This study found a significant age-dependent association between alopecia areata and atopic dermatitis, with atopic dermatitis being a notable risk factor, especially in children.

This review examines the interconnected processes of atopic dermatitis and alopecia areata, highlighting shared immune imbalances, genetic factors, and microbiome influences, while analyzing current and emerging treatments and identifying gaps in understanding these overlapping conditions.

In this study, researchers identified immune differences in children with alopecia areata, finding that cytokine profiles vary based on the presence of atopic diseases; notably, patients with atopy showed a heightened T helper 2 response, potentially influencing cytokine expression and disease severity.

This review highlights that dysbiosis in skin and scalp microbiomes is linked to both atopic dermatitis and androgenetic alopecia, suggesting that microbial composition influences disease progression.

Probiotics significantly reduce the severity of atopic dermatitis.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

In this case series conducted in Austrian dermatology clinics, tralokinumab was found to be a well-tolerated and effective long-term treatment for adults with moderate-to-severe atopic dermatitis, with improvements in eczema severity and symptom suppression maintained over up to three years.

This qualitative review reports a high socioeconomic impact of atopic dermatitis and alopecia areata, emphasizing significant quality of life reductions and increased costs, but highlights a lack of comprehensive data from many regions worldwide, underscoring the need for global studies with standardized methodologies.

In a mice model of atopic dermatitis, this study reported that a formulated cromolyn sodium oleate gel significantly reduced scab size and provided better healing than dexamethasone, with fewer adverse effects.

This study reviewed literature and assessed clinical data on treating alopecia areata linked with atopic diseases, finding that therapies like dupilumab, phototherapy, and JAK inhibitors may address overlapping symptoms, suggesting a focus on reducing pharmacological burden and enhancing quality of life.

This case report highlights that Baricitinib led to significant hair regrowth and resolution of atopic dermatitis symptoms in a 22-year-old female with coexisting autoimmune conditions.

In this study, JAK inhibitors significantly improved outcomes for patients with both atopic dermatitis and alopecia areata, while dupilumab was linked to worsening alopecia in some cases.

This case report describes a child with alopecia areata and atopic dermatitis who showed significant improvement after treatment with baricitinib and corticosteroid ointment, suggesting their potential efficacy and safety.

In this observational study, researchers examined U.S. and Canadian patients with alopecia areata and found that while comorbid anxiety/depression correlated with increased patient-reported disease severity, other comorbidities like atopic dermatitis and vitiligo showed no statistically significant differences in clinician-reported AA severity or hair involvement.

This study found that atopic diseases such as atopic dermatitis, asthma, and allergic rhinitis increase the risk of developing alopecia areata, suggesting a significant role for T cell-related inflammation in the condition's mechanism.

This study reported that dupilumab led to significant reduction in skin rash severity and complete hair regrowth in an 11-year-old boy with severe alopecia areata and atopic dermatitis.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

In this study, thymic stromal lymphopoietin (TSLP) induced IL-4/IL-13 from T cells, prompting sebum secretion and adipose loss, suggesting IL-4/IL-13 may affect skin barrier function in atopic dermatitis.

In this case report, an 8-year-old with severe alopecia areata and atopic dermatitis experienced significant hair regrowth and improved dermatitis symptoms after treatment with dupilumab followed by baricitinib, with no major side effects observed.

This study examined 162 patients and found that those with both alopecia areata and atopic diseases showed higher cases of severe alopecia in children and a tendency for combined atopic diseases. Sensitization patterns were similar between alopecia areata patients and those with atopic diseases alone.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

This study found that topical immunotherapy was effective in 56.83% of pediatric patients with alopecia areata, but those with co-occurring atopic dermatitis were more likely to show an inadequate response to treatment.

This commentary piece identifies interleukin-13 as a potential therapeutic target for treating alopecia areata associated with atopic dermatitis, although specific study results or outcomes are not provided in the abstract.

In this study, topical application of adipose stem cell exosomes was found to reduce facial redness in atopic dermatitis patients treated with dupilumab, while improving skin hydration and decreasing inflammation markers over 12 weeks.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

Adipose stem cell exosomes may effectively treat atopic dermatitis by reducing inflammation and improving skin health.